Aurisco Pharmaceutical Co.,Ltd. (605116.SS)
CNY 20.8
(-0.48%)
CNY 20.8
(-0.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 375.24 Million CNY | 40.17% |
| 2022 | 292.04 Million CNY | 44.26% |
| 2021 | 202.43 Million CNY | 42.43% |
| 2020 | 142.13 Million CNY | 10.15% |
| 2019 | 129.03 Million CNY | 17.96% |
| 2018 | 109.38 Million CNY | -39.3% |
| 2017 | 180.2 Million CNY | -15.26% |
| 2016 | 212.64 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 102.63 Million CNY | -9.4% |
| 2024 Q1 | 92.14 Million CNY | -26.2% |
| 2024 Q2 | 119.79 Million CNY | 30.01% |
| 2023 Q4 | 124.86 Million CNY | 3.56% |
| 2023 FY | 409.35 Million CNY | 40.17% |
| 2023 Q3 | 120.57 Million CNY | 33.69% |
| 2023 Q2 | 90.19 Million CNY | 22.34% |
| 2023 Q1 | 73.72 Million CNY | -24.44% |
| 2022 Q3 | 67.55 Million CNY | 14.87% |
| 2022 FY | 292.04 Million CNY | 44.26% |
| 2022 Q2 | 58.81 Million CNY | -13.66% |
| 2022 Q1 | 68.11 Million CNY | 1.01% |
| 2022 Q4 | 97.56 Million CNY | 44.42% |
| 2021 Q2 | 50.16 Million CNY | 37.15% |
| 2021 Q1 | 36.57 Million CNY | 17.78% |
| 2021 Q4 | 67.43 Million CNY | 39.73% |
| 2021 Q3 | 48.26 Million CNY | -3.79% |
| 2021 FY | 202.43 Million CNY | 42.43% |
| 2020 Q1 | 34.53 Million CNY | -18.86% |
| 2020 FY | 142.13 Million CNY | 10.15% |
| 2020 Q4 | 31.05 Million CNY | -19.95% |
| 2020 Q3 | 38.79 Million CNY | 2.79% |
| 2020 Q2 | 37.74 Million CNY | 9.27% |
| 2019 Q4 | 42.56 Million CNY | 30.13% |
| 2019 Q3 | 32.71 Million CNY | 0.0% |
| 2019 FY | 129.03 Million CNY | 17.96% |
| 2018 FY | 109.38 Million CNY | -39.3% |
| 2017 FY | 180.2 Million CNY | -15.26% |
| 2016 FY | 212.64 Million CNY | 0.0% |